These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35263216)

  • 1. Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.
    Wang L; Yang X; Zhou F; Sun X; Li S
    Bioengineered; 2022 Mar; 13(3):7197-7208. PubMed ID: 35263216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling.
    Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D
    Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Gu Y; Fei Z; Zhu R
    Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer.
    Wu K; Hu Y; Yan K; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
    J Cell Physiol; 2020 Feb; 235(2):1247-1258. PubMed ID: 31267531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circular RNA SET domain protein 3 promotes nasopharyngeal carcinoma proliferation, cisplatin resistance, and protein kinase B / mammalian target of rapamycin pathway activation by modulating microRNA-147a expression.
    Deng G; Wang F; Song Y
    Bioengineered; 2022 Mar; 13(3):5843-5854. PubMed ID: 35196205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
    Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
    Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
    Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
    Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.
    Song L; Zhou Z; Gan Y; Li P; Xu Y; Zhang Z; Luo F; Xu J; Zhou Q; Dai F
    J Cell Biochem; 2019 Jun; 120(6):9656-9666. PubMed ID: 30548308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
    Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
    Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
    Cheng C; Qin Y; Zhi Q; Wang J; Qin C
    Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
    Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
    Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
    Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling.
    DA X; Ge H; Shi J; Zhu C; Wang G; Fang Y; Xu J
    Oncol Res; 2024; 32(7):1209-1219. PubMed ID: 38948021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis.
    Liu H; Zhang J; Luo X; Zeng M; Xu L; Zhang Q; Liu H; Guo J; Xu L
    Oncol Res; 2020 Feb; 28(1):65-73. PubMed ID: 31558183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling.
    Ni Q; Zhang Y; Tao R; Li X; Zhu J
    Aging (Albany NY); 2021 Mar; 13(6):8665-8687. PubMed ID: 33714198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.